Ichihashi T, Izawa M, Miyata K, Mizui T, Hirano K, Takagishi Y
Formulation R & D Laboratories, Shionogi & Co., Ltd., Osaka, Japan.
J Pharmacol Exp Ther. 1998 Jan;284(1):43-50.
The mechanism of the hypocholesterolemic action of S-8921, methyl 1-(3,4-dimethoxyphenyl)-3-(3-ethylvaleryl)- 4-hydroxy-6,7,8-trimethoxy-2-naphthoate, was examined in rats. In diet-induced hypercholesterolemic rats, 2 weeks oral administration of S-8921 dose- and time-dependently decreased plasma cholesterol level in the daily dose range of 0.1 to 10 mg/kg. Results with the dual-isotope plasma ratio method indicated that S-8921 inhibits cholesterol absorption from the intestine and enhances its elimination from the body. The in situ loop method showed that S-8921 does not inhibit the absorption of cholesterol from rat jejunum, clearly inhibits active absorption of taurocholic acid (TCA) and glycocholic acid (GCA) from rat ileum and does not inhibit passive absorption of cholic acid (CA) from the rat jejunum. In rat ileal brush-border membrane vesicles, S-8921 inhibited the sodium-dependent uptake of TCA in a concentration-dependent manner with IC50 of 2.1 microM, not the Na(+)-dependent D-glucose and L-alanine uptake. These results suggest that S-8921 is a potent, selective inhibitor of the Na(+)-dependent bile acid transport system in the ileal mucosal cell brush-border membrane, and this inhibition is the mechanism by which this drug decreases intestinal bile acid reabsorption to result in a significant decrease of plasma cholesterol.
在大鼠中研究了S-8921(1-(3,4-二甲氧基苯基)-3-(3-乙基戊酰基)-4-羟基-6,7,8-三甲氧基-2-萘甲酸甲酯)降胆固醇作用的机制。在饮食诱导的高胆固醇血症大鼠中,连续2周口服S-8921,在每日剂量范围为0.1至10mg/kg时,血浆胆固醇水平呈剂量和时间依赖性降低。双同位素血浆比率法的结果表明,S-8921抑制胆固醇从肠道的吸收并增强其从体内的清除。原位肠袢法表明,S-8921不抑制大鼠空肠胆固醇的吸收,明显抑制大鼠回肠牛磺胆酸(TCA)和甘氨胆酸(GCA)的主动吸收,不抑制大鼠空肠胆酸(CA)的被动吸收。在大鼠回肠刷状缘膜囊泡中,S-8921以浓度依赖性方式抑制TCA的钠依赖性摄取,IC50为2.1μM,而不抑制Na(+)-依赖性D-葡萄糖和L-丙氨酸的摄取。这些结果表明,S-8921是回肠粘膜细胞刷状缘膜中Na(+)-依赖性胆汁酸转运系统的有效、选择性抑制剂,这种抑制作用是该药物减少肠道胆汁酸重吸收从而导致血浆胆固醇显著降低的机制。